Ligand Pharmaceuticals Incorporated
LGND
Clasificación en acciones
#3103
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Precio por acción
$291.18
Última sincronización: 2026-07-31
Capitalización bursátil
$5.84B
Cambio (1 día)
-1.73%
Cambio (1 año)
55.99%
País
US
Comercio Ligand Pharmaceuticals Incorporated (LGND)
Categoría
Healthcare
Ratio P/E de Ligand Pharmaceuticals Incorporated (LGND)
Ratio P/E al October 2026 TTM: 29.47
Según los últimos informes financieros y el precio de las acciones de Ligand Pharmaceuticals Incorporated, el P/E actual (TTM) de la empresa es 29.47. Al final de 2023, la empresa tenía un P/E de 23.69.
Historial del ratio P/E de Ligand Pharmaceuticals Incorporated desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 29.47 | -106.06% |
| 2024 | -486.05 | -2,151.90% |
| 2023 | 23.69 | -170.13% |
| 2022 | -33.78 | -175.13% |
| 2021 | 44.96 | -108.34% |
| 2020 | -539.23 | -17,229.80% |
| 2019 | 3.15 | -86.17% |
| 2018 | 22.77 | -90.07% |
| 2017 | 229.37 | -117.73% |
| 2016 | -1.29K | -15,615.10% |
| 2015 | 8.34 | -90.77% |
| 2014 | 90.36 | -3.41% |
| 2013 | 93.55 | -112.45% |
| 2012 | -751.68 | -3,378.49% |
| 2011 | 22.93 | -264.01% |
| 2010 | -13.98 | -88.91% |
| 2009 | -126.08 | 4,626.87% |
| 2008 | -2.67 | -258.53% |
| 2007 | 1.68 | -106.05% |
| 2006 | -27.81 | 96.61% |
| 2005 | -14.14 | -25.56% |
| 2004 | -19.00 | -31.44% |
| 2003 | -27.72 | 290.20% |
| 2002 | -7.10 | -53.97% |
| 2001 | -15.43 | 129.72% |
| 2000 | -6.72 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | -2.33% |
US
|
|
| -28.36 | -196.23% |
US
|
|
| -24.57 | -183.36% |
AU
|
|
| 30.33 | 2.92% |
NL
|
|
| - | - |
CH
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.